

**INDEPENDENT AUDITOR'S REPORT****TO THE MEMBERS OF SURAKSHA DIAGNOSTIC & EYE CENTRE
PRIVATE LIMITED****Report on the Audit of the Consolidated Financial Statements****Opinion**

We have audited the accompanying Consolidated Financial Statements of **Suraksha Diagnostic & Eye Centre Private Limited** (hereinafter referred to as the 'Parent Company') and its associates, which comprise the Consolidated Balance Sheet as at March 31, 2023, and the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Company as at March 31, 2023, of consolidated profit, and its consolidated cash flows for the year then ended.


Basis for Opinion

We conducted our audit in accordance with Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Parent Company and its associates, in accordance with the *Code of Ethics* and provisions of the Companies Act, 2013 that are relevant to our audit of the consolidated financial statements in India under the Companies Act, 2013, and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics and the requirements under the Companies act, 2013. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Information other than the Consolidated Financial Statements and Auditor's Report thereon

The Parent Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Parent Company's Annual Report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



BRANCH :

9/12 LAL BAZAR STREET, 'E' BLOCK, 1ST FLOOR, MERCANTILE BUILDING, KOLKATA - 700 001
INDIRA NAGAR, KANKE ROAD, RANCHI-834 008, JHARKHAND, M : 91-9471186522

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the Financial Statements

The Parent Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in term of the requirements of the Companies Act, 2013 that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Parent Company including its Associates in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the Parent Company and of its associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Parent Company and its associates and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Parent Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the Parent Company and of its associates are responsible for assessing the ability of the Parent Company and of its associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Parent Company and of its associates are responsible for overseeing the financial reporting process of the Parent Company and of its associates.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:



Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Consolidated Financial Statements include the Parent Company's share of net loss of ` 61.21 Hundred for the year ended 31st March, 2023, as considered in the Consolidated Financial Statements, in respect of 2 (two) associates, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these associates, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, in so far as it relates to the aforesaid associates is based solely on the reports of the other auditors.

Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to



our reliance on the work done and the reports of the other auditors and the financial statements / financial information certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
- b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
- c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors of the Parent Company as on 31st March, 2023 taken on record by the Board of Directors of the Parent Company and the reports of the statutory auditors of its associate companies incorporated in India, none of the directors of the Parent Company and its associate companies incorporated in India is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i) There were no pending litigations which would impact the consolidated financial position of the Parent Company and its associates.
 - ii) The Parent Company and its associates did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Parent Company and its associate companies incorporated in India.
 - iv) Based on the written representation received from the management that to the best of its knowledge and belief,



- a) No funds have been advanced or loaned or invested by the company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- b) No funds have been received by the company from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- v) During the year the Company has not declared any dividend.
2. With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor’s Report) Order, 2020 (“CARO”/ “the Order”) issued by the Central Government in terms of Section 143(11) of the Act, according to the information and explanations given to us, and based on the CARO reports issued by us and the auditors of respective companies included in the consolidated financial statements to which reporting under CARO is applicable, as provided to us by the Management of the Parent, we report that there are no qualifications or adverse remarks by the respective auditors in the CARO reports of the said respective companies included in the consolidated financial statements.
3. With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended, the same is not applicable to the Parent Company and its associates which are incorporated in India, them being private companies.

**FOR K. S. BOTHRA & CO.
CHARTERED ACCOUNTANTS
FIRM REGISTRATION NO. 304084E**

Arum
**(A. VERMA)
PARTNER
MEMBERSHIP NO. 061326
ICAI UDIN: 23061326BGVMAB6211
KOLKATA, THE 23RD DAY OF SEPTEMBER, 2023**



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
CIN: U85110WB1991PTC052153
Regd. Office: P 118 C I T ROAD SCHEME VIM, KOLKATA 700054
CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH 2023

PARTICULARS	31.03.2023 (Rupees in '00)	31.03.2022 (Rupees in '00)
<u>EQUITY AND LIABILITIES</u>		
<u>Shareholders' Funds</u>		
Share Capital. 2	68,100.00	90,800.00
Reserve and Surplus. 3	16,29,609.57	21,01,786.32
(A)	16,97,709.57	21,92,586.32
Minority Interest (B)	-	-
<u>Current Liabilities</u>		
Trade Payables 4	1,37,277.82	81,864.96
Other Current Liabilities 5	25,149.10	4,998.13
Short Term Provisions 6	1,62,855.71	4,00,851.83
(C)	3,25,282.63	4,87,714.92
TOTAL : (A+B+C)	20,22,992.20	26,80,301.24
<u>ASSETS</u>		
<u>Non-Current Assets</u>		
<u>Property , Plant and Equipment and Intangible assets</u>		
i) Property , Plant & Equipment		
Non Current Investments 8	3,409.35	3,698.16
Other Non-Current Assets 9	8,24,368.53	8,80,176.33
(A)	8,60,353.75	9,16,450.36
<u>Current Assets</u>		
Current Investments 10	1,03,459.45	1,03,459.45
Inventories 11	1,01,465.15	97,494.00
Trade Receivables 12	1,73,710.65	1,10,978.36
Cash and Cash Equivalents 13	1,39,985.89	5,63,424.63
Short Term Loans & Advances 14	6,37,320.52	8,84,326.91
Other Current Assets 15	6,696.79	4,167.54
(B)	11,62,638.45	17,63,850.88
TOTAL : (A+B)	20,22,992.20	26,80,301.24


Significant Accounting Policies 1

Accompanying Notes form integral part of the consolidated financial Statements.

FOR K. S. BOTHRA & CO.
 CHARTERED ACCOUNTANTS
 FIRM REGISTRATION NO. 304084E

(A. VERMA)
 PARTNER
 MEMBERSHIP NO. 061326
 ICAI UDIN: 23061326BGVMAB6211
 KOLKATA, THE 23RD DAY OF SEPTEMBER, 2023



For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

 Director
 DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

 Director
 DIN:- 00137075

SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED

CIN: U85110WB1991PTC052153

Regd. Office: P 118 C I T ROAD SCHEME VIM, KOLKATA 700054

CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2023

PARTICULARS		31.03.2023 (Rupees in '00)	31.03.2022 (Rupees in '00)
Income :			
Revenue from Operations	16	7,91,105.17	13,71,710.22
Other Income.	17	67,083.02	89,161.23
Total Income		8,58,188.19	14,60,871.45
Expenses:			
Purchase of Shares		3,22,807.16	10,87,332.49
Changes in Inventories	18	(3,971.15)	(57,573.23)
Employee Benefits Expenses	19	29,280.00	29,280.00
Depreciation		288.81	325.93
Other Expenses	20	4,39,513.83	3,20,335.86
Total Expenses		7,87,918.64	13,79,701.06
Profit before Tax		70,269.55	81,170.39
Tax Expenses:			
Current tax		15,258.81	21,232.10
Tax relating to earlier years		(171.26)	(138.00)
Profit after Tax		55,182.00	60,076.29
Add: Share of Profit of Associate		(61.21)	(372.09)
Profit for the year		55,120.79	59,704.20
Earnings per equity share:	21		
-Basic and Diluted (₹)		60.71	65.75
Significant Accounting Policies	1		

Accompanying Notes form integral part of the consolidated financial Statements.


FOR K. S. BOTHRA & CO.
CHARTERED ACCOUNTANTS
FIRM REGISTRATION NO. 304084E

(A. VERMA)
PARTNER
MEMBERSHIP NO. 061326
ICAI UDIN: 23061326BGVMAB6211
KOLKATA, THE 23RD DAY OF SEPTEMBER, 2023

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


Director
DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023

1. SIGNIFICANT ACCOUNTING POLICIES ON CONSOLIDATED ACCOUNTS:

1.1 **Basis of Preparation:**

These consolidated financial statements have been prepared to comply with the Generally Accepted Accounting Principles in India (Indian GAAP), including the Accounting Standards notified under the relevant provisions of the Companies Act, 2013.

The consolidated financial statements have been prepared under the historical cost convention on an accrual basis. The accounting policies applied by the Group Companies are consistent with those used in the previous year.

1.2 **Associate Companies Considered in the Consolidated Financial Statement:**

Name of the Company	Country of Incorporation	Proportion of Ownership Interest
<u>Associate:</u>		
Reema Gases Private Limited	India	28.62%
C. K. Trade-Ex Private Limited	India	24.29%

1.3 **Principles of Consolidation:**

The consolidated financial statements relate to Suraksha Diagnostic & Eye Centre Private Limited ('the Company') and its associates. The consolidated financial statements have been prepared on the following basis:

a) Investment in Associate Companies has been accounted under the equity method as per Accounting Standard (AS) 23 - "Accounting for Investments in Associates in Consolidated Financial Statements".

b) The Company accounts for its share of post-acquisition changes in net assets of associates, after eliminating unrealised profits and losses resulting from transactions between the Company and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss, to the extent such change is attributable to the associates' Statement of Profit and Loss and through its reserves for the balance based on available information.

c) The difference between the cost of investment in the associates and the share of net assets at the time of acquisition of shares in the associates is identified in the financial statements as Goodwill or Capital Reserve, as the case may be, and the same has been disclosed separately alongwith the investment value.

d) As far as possible, the consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented in the same manner as the Company's separate financial statements.


1.4 **Investments:**

Investments other than in subsidiaries have been accounted as per Accounting Standard (AS) 13 on "Accounting for Investments".


1.5 **Other significant accounting policies**

These are set out under "Significant Accounting Policies" as given in the Company's separate financial statements.

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


Director
DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTD.....)

	31.03.2023	31.03.2022
	(Rupees in '00)	(Rupees in '00)
2 SHARE CAPITAL :		
Authorised :		
200000 Equity Shares of `100/- each.	2,00,000.00	2,00,000.00
Issued, Subscribed and Paid up :		
68100 (PY-90800) Equity Shares of `100/-each fully paid up	68,100.00	90,800.00
	68,100.00	90,800.00

2.1 Reconciliation of No. of Outstanding Shares at the beginning and at the end of the year

For Equity Share :

Outstanding Shares at the beginning of year	90800	90800
Less :- Buyback 22700 Equity Shares	22700	0
Outstanding Shares at the end of year	68100	90800

2.2 Terms / rights attached to Equity Shares :

The Company has single class of shares referred to as Equity Shares having a par value of `100/- each. Each Holder of Equity Shares is entitled to one vote per share. Dividend on such shares is payable in proportion to the paid up amount. Dividend (if any) recommended by board of directors (other than interim dividend) is subject to approval of the shareholders in the ensuing Annual General Meeting.

In the event of winding up of the company, the holder of Equity Shares will be entitled to receive any of the remaining assets of the company after all preferential amounts and external liabilities are paid in full. The distribution of such remaining assets will be on the basis of number of Equity Shares held and the amount paid up on such shares.

2.3 Shareholders holding more than 5% of the Shares of the Company

Shareholders Name	31.03.2023		31.03.2022	
	% of holding	No. of Shares held	% of holding	No. of Shares held
Dr. Tandra Chatterjee	14.32%	13001	19.09%	17335
Dr. Gautam Ghosh	13.84%	12568	18.45%	16757
Sarla Kejriwal	7.84%	7120	10.45%	9493
Kusum Kejriwal	9.24%	8386	12.31%	11181
Uma Kejriwal	7.13%	6472	9.50%	8630
Bindu Kejriwal	15.34%	13929	20.45%	18572

2.4 Shares Held by Promoters at the End of the year

Promoter Name	31.03.2023		31.03.2022	
	No. of Shares as on	% of Total Shares	No. of Shares as on	% of Total Shares
Dr. Somnath Chatterjee	2476	3.64%	3302	3.64%
Dr. Tandra Chatterjee	13001	19.09%	17335	19.09%
Dr. Gautam Ghosh	12568	18.46%	16757	18.45%
Suparna Ghosh	2910	4.27%	3880	4.27%
Kishan Kumar Kejriwal	619	0.91%	825	0.91%
Santosh Kumar Kejriwal	619	0.91%	825	0.91%
Sarla Kejriwal	7120	10.46%	9493	10.45%
Kusum Kejriwal	8386	12.31%	11181	12.31%
Uma Kejriwal	6472	9.50%	8630	9.50%
Bindu Kejriwal	13929	20.45%	18572	20.45%

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
Director
DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
Notes to the Consolidated Financial Statements (Contd...)

	31.03.2023 (Rupees in '00)	31.03.2022 (Rupees in '00)
3 RESERVE AND SURPLUS :		
Capital Redemption Reserve		
Opening Balance	30,200.00	30,200.00
Ass:-Transferred from Balance in Statement of Profit & Loss	22,700.00	-
(A)	52,900.00	30,200.00
General Reserve		
As per last Balance Sheet	1,01,610.00	1,01,610.00
(B)	1,01,610.00	1,01,610.00
Balance in Statement Profit and Loss :		
Surplus as per last Balance Sheet	19,69,976.32	19,32,972.12
Less: Dividend	-	22,700.00
	19,69,976.32	19,10,272.12
Less:- Capital Redemption Reserve		
Buyback 22700 shares of `100/- each at premium of `1884/-	22,700.00	-
Tax on Shares Buyback	99,629.54	-
Premium on Buy-back of Shares	4,27,668.00	-
	14,19,978.78	19,10,272.12
Add: Profit for the year	55,120.79	59,704.20
(C)	14,75,099.57	19,69,976.32
(A+B+C)	16,29,609.57	21,01,786.32
4 TRADE PAYABLES		
For Goods and Services		
Total outstanding dues of Micro and Small Enterprises	-	-
Other outstanding dues	1,37,277.82	81,864.96
(Refer Ageing Schedule No. 23)	1,37,277.82	81,864.96
5 OTHER CURRENT LIABILITIES		
Other Payables		
- Statutory Liabiliteis	3,615.37	4,674.13
- Others Liabilities	21,533.73	324.00
	25,149.10	4,998.13
6 SHORT TERM PROVISIONS		
Provision for Income Tax	1,62,855.71	4,00,851.83
	1,62,855.71	4,00,851.83
8 NON CURRENT INVESTMENTS		
In Equity Intruments: (Quoted) (At Cost)		
25000 Equity Shares of `10/- each of Infomedia18 Ltd.	8,375.00	8,375.00
336 Equity Shares of Parsvnath Developers Limited of `10/- each.	504.00	504.00
1247000 Equity Shares of Ishwar Medical Services Ltd of `1/- each.	10,705.10	10,705.10
81203 Equity Shares of Vodafone Idea Limited of `10/- each.	10,150.38	10,150.38
(a)	29,734.48	29,734.48
In Equity Intruments: (Unquoted) (At Cost)		
In Associate Companies:		
2000000 Equity Shares of Reema Gases Pvt. Ltd. of `10/- each (Goodwill - `48248261/-, P.Y. - `48248261/-)	1,36,272.96	1,36,426.21
5800000 (P.Y. 4300000) Equity Shares of C.K.Trade Ex Pvt Ltd of `10/- each (Goodwill - `53991285/-, P.Y. - `53991285/-)	5,50,983.06	5,50,891.02
(b)	6,87,256.02	6,87,317.23

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

Director
DIN:- 00137075

SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTD.....)

NOTE - 7

PROPERTY, PLANT AND EQUIPMENT :

Particulars.	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at 01.04.2022	Addition during the year.	Sales/adj during the year.	As at 31.03.2023	Upto 31.03.2022	For the year.	Adjustment during the year.	Upto 31.03.2023	As at 31.03.2023	As at 31.03.2022
(Rupees in '00)										
Tangible Assets:										
Motor Car.	51,071.44	-	-	51,071.44	48,517.87	-	-	48,517.87	2,553.57	2,553.57
Air Conditioner.	1,632.40	-	-	1,632.40	1,550.78	-	-	1,550.78	81.62	81.62
Computer.	736.16	-	-	736.16	699.35	-	-	699.35	36.81	36.81
Furniture & Fixture	870.34	-	-	870.34	440.50	82.69	-	523.19	347.15	429.84
Office Equipments	1,337.02	-	-	1,337.02	853.23	185.33	-	1,038.56	298.46	483.79
UPS System.	450.00	-	-	450.00	337.47	20.79	-	358.26	91.74	112.53
TOTAL :	56,097.36	-	-	56,097.36	52,399.20	288.81	-	52,688.01	3,409.35	3,698.16
Previous Year's figures	56,097.36	-	-	56,097.36	52,073.27	325.93	-	52,399.20	3,698.16	



For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.
[Signature]
 Director
 DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.
[Signature]
 Director
 DIN:- 00137075

SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
Notes to the Consolidated Financial Statements (Contd...)

	31.03.2023 (Rupees in '00)	31.03.2022 (Rupees in '00)
8 NON CURRENT INVESTMENTS		
<u>In Equity Instruments: (Unquoted) (At Cost)</u>		
<u>In Other Companies:</u>		
20000 Equity Shares of Suraksha Diagnostic Private Limited of `100/- each.	20,000.00	20,000.00
Nil(P.Y-25000) Equity Shares of Saltee Parks Private Limited of `10/- each	-	50,000.00
(c)	20,000.00	70,000.00
(A=a+b+c)	7,36,990.50	7,87,051.71
<u>Other Investments:</u>		
Indiabulls High Yield Fund	87,378.03	93,124.62
(B)	87,378.03	93,124.62
(A+B)	8,24,368.53	8,80,176.33
Market Value of Quoted Equity Instruments	6,915.57	10,396.29
9 OTHER NON-CURRENT ASSETS		
<u>(Unsecured, considered good)</u>		
Security Deposits	32,575.87	32,575.87
	32,575.87	32,575.87
10 CURRENT INVESTMENTS:		
<u>Investments in Mutual Fund:</u>		
2592.149 HDFC Liquid Fund Regular Growth	1,03,459.45	1,03,459.45
	1,03,459.45	1,03,459.45
NAV of Mutual Fund	1,07,620.78	1,07,620.78
11 INVENTORIES :		
(At cost or net realisable value, whichever is lower as per inventories taken, valued and certified by the management)		
Shares	1,01,465.15	97,494.00
	1,01,465.15	97,494.00
12 TRADE RECEIVABLES		
<u>(Unsecured, considered good)</u>		
Trade Receivables:	1,73,710.65	1,10,978.36
(Refer Ageing Schedule No. 24)	1,73,710.65	1,10,978.36
13 CASH AND CASH EQUIVALENTS		
Balances with Scheduled Banks :		
In Current Accounts.	45,608.08	64,512.56
In Fixed Deposit Accounts.	94,064.73	4,98,488.99
Cash on hand (As Certified)	313.08	423.08
	1,39,985.89	5,63,424.63
14 SHORT TERM LOANS AND ADVANCES :		
<u>(Unsecured, considered good)</u>		
<u>Loan to Body Corporates:</u>		
To a Related Party	3,83,950.69	3,75,000.00
<u>Advances:</u>		
(Recoverable in cash or in kind or for value to be received pending adjustments)		
Income Tax Payments	1,95,762.02	4,56,127.93
Income Tax (Under Protest) - AY 2017-18	5,000.00	5,000.00

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
 Director
 DIN:- 00137133



For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
 Director
 DIN:- 00137075

SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
Notes to the Consolidated Financial Statements (Contd...)

	31.03.2023	31.03.2022
	(Rupees in '00)	(Rupees in '00)
14 SHORT TERM LOANS AND ADVANCES :(Cont....)		
Advance Payments of TDS	5,080.09	5,080.09
Income Tax Refundable	11,580.96	11,280.96
Income Tax Refundable A.Y. 2022-2023	2,914.30	-
Income Tax Refundable (AY 2019- 20)	3,718.37	-
Other Advances	29,314.10	31,837.93
	6,37,320.52	8,84,326.91
15 OTHER CURRENT ASSETS:		
Income Receivable on Investments	6,696.79	4,167.54
	6,696.79	4,167.54
16 REVENUE FROM OPERATIONS:		
Fees & Services Charges Received	4,57,822.70	3,25,462.20
Sale of Shares	3,33,282.47	10,46,248.02
	7,91,105.17	13,71,710.22
17 OTHER INCOME :		
Interest Received :		
On Loans	30,000.01	28,630.14
On Fixed Deposits	13,766.44	15,167.39
On Security Deposits.	1,531.56	1,535.74
On income Tax Refund	281.29	-
Rental Charges Received	6.00	6.00
Dividend Received on Shares	11,044.53	15,494.50
Income from Alternate Investment Fund	10,273.70	2,772.24
Income on Investment (Liquid Gold Series)	-	14,678.38
Income from F & O	-	(469.60)
Liability No Longer Required written back	179.48	11,346.45
	67,083.02	89,161.23
18 CHANGES IN INVENTORIES		
Opening Stock: Shares	97,494.00	39,920.77
Less: Closing Stock of Shares	1,01,465.15	97,494.00
	(3,971.15)	(57,573.23)
19 EMPLOYEE BENEFITS EXPENSES:		
Directors Remuneration.	29,280.00	29,280.00
Staff Refreshment Expenses	-	-
	29,280.00	29,280.00
20 OTHER EXPENSES :		
Testing Charges	3,43,367.05	2,44,096.66
NRS Poor Patients Welfare Expenses	91,564.54	65,092.44
Insurance Charges.	375.59	345.37
Share Transaction Expenses	1,377.81	3,968.14
Motor Car Expenses	815.54	795.72
Auditors' Remuneration:		
For Audit & Tax Audit.	300.00	300.00
For Advice on Company Law Matters.	540.00	540.00
For Advice on Taxation & Other Matters.	484.55	357.70
Filing Fees	55.00	18.00
Rates & Taxes.	50.00	219.36

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


 Director
 DIN:- 00137133




For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


 Director
 DIN:- 00137075

SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
Notes to the Consolidated Financial Statements (Contd...)

	31.03.2023 (Rupees in '00)	31.03.2022 (Rupees in '00)
20 OTHER EXPENSES :(Cont....		
Bank Charges.	33.06	20.23
Professional Fees	300.00	-
Miscellaneous Expenses	4.97	4,169.90
Interest on TDS	245.71	162.35
Trade Mark Charges	-	250.00
	4,39,513.83	3,20,335.86
21 EARNINGS PER SHARE		
Profit for the year after Tax	55120.79	59704.20
No. of Issued, Subscribed & Paid up shares	90800	90800
Basic & Diluted	0.61	0.66
Basic & Diluted (in Rs.)	60.71	65.75

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

 Director
 DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

 Director
 DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (Contd.....)


NOTE: 22

Trade Payables Ageing:


Particulars	Outstanding for following periods from due date of payment 31.03.2023				Total
	Less than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	1,37,277.82	-	-	-	1,37,277.82
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-

Particulars	Outstanding for following periods from due date of payment 31.03.2022				Total
	Less than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	59,093.84	179.48	-	22,591.64	81,864.96
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


 Director
 DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.


 Director
 DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (Contd.....)

NOTE: 23

Trade Receivables Ageing:

(` In Hundred)

Particulars	Outstanding for following periods from due date of payment as on 31.03.2023					Total
	Less than 6 months	6 months 1 year	1-2 years	2-3 years	More than 3 years	
SECURED:						
Undisputed Trade Receivables – considered good	-	-	-	-	-	-
Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables – considered good	-	-	-	-	-	-
Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-
UNSECURED:						
Undisputed Trade Receivables – considered good	1,24,262.20	-	-	52.40	49,396.05	1,73,710.65
Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables – considered good	-	-	-	-	-	-
Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-

Particulars	Outstanding for following periods from due date of payment as on 31.03.2022					Total
	Less than 6 months	6 months 1 year	1-2 years	2-3 years	More than 3 years	
SECURED:						
Undisputed Trade Receivables – considered good	-	-	-	-	-	-
Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables – considered good	-	-	-	-	-	-
Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-
UNSECURED:						
Undisputed Trade Receivables – considered good	-	-	52.40	-	1,10,925.96	1,10,978.36
Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables – considered good	-	-	-	-	-	-
Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd. (2)

Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd. (3)

Director
DIN:- 00137075



SURAKSHA DIAGNOSTIC & EYE CENTRE PRIVATE LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023.

	31.03.2023 (In ₹ Hundred)	31.03.2022 (In ₹ Hundred)
24. Expenditure in Foreign Currency	Nil	Nil
25. Earnings in Foreign Currency	-	Nil
26. Contingent Liabilities	Nil	Nil

27. Related Party Disclosures:

Enterprises where key management personnel or their relatives have significant influence and other parties which are related with the key management personnel: (Where transactions have taken place)

Dr. Somnath Chatterjee	Director of the Company
Dr. Gautam Ghosh.	Director of the Company
Dr. (Mrs.) Tandra Chatterjee	Director of the Company
Dr. (Mrs.) Suparna Ghosh	Director of the Company
Mr. Kishan Kumar Kejriwal	Director of the Company
Mrs. Kusum Kejriwal	Director of the Company
Mrs. Seema Kejriwal	Director of the Company
Mr. Vishal Kejriwal	Director of the Company
Mrs. Usha Devi Bardia	Director of the Company
Reema Gases Private Limited	Associate Company
C. K. Trade Ex Private Limited	Associate Company
Suraksha Diagnostic Private Limited	Company under the same management
Poojit Commercial Private Limited	Company under the same management

Related Party Relationship in terms of Accounting Standard (AS) – 18, Related Party Disclosure, as specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, have been certified by the management and relied upon by the Auditors.

The following related party transactions were carried out during the year in the ordinary course of business

Loan Given

(₹ in Hundred)

Transaction with	Opening Balance	Amount Given	Interest	TDS	Repayment	Closing Balance
Poojit Commercial Private Limited	375000.00 (331671.41)	0.00 (50000.00)	30000.01 (28630.14)	3000 (2863.02)	18049.32 (32438.53)	383950.69 (375000.00)

Previous Year's figures in ()

Other Transactions:

(Amount in ₹ Hundred)

Account Head	Transaction with	31.03.2023	31.03.2022
Income:			
Interest Received	Poojit Commercial Private Limited	30000.01	28630.14
Expenses:			
Directors' Remuneration.	Dr. Somnath Chatterjee.	6000.00	6000.00
	Dr. Gautam Ghosh.	6000.00	6000.00
	Dr. (Mrs.) Tandra Chatterjee.	2640.00	2640.00
	Dr. (Mrs.) Suparna Ghosh.	2640.00	2640.00
	Mrs. Kusum Kejriwal	2880.00	2880.00
	Mrs. Seema Kejriwal	2880.00	2880.00
	Mr. Vishal Kejriwal	2880.00	2880.00
	Mr. Kishan Kumar Kejriwal	2880.00	2880.00
	Mrs. Usha Devi Bardia	480.00	480.00
Testing Charges	Suraksha Diagnostic Private Limited	343367.05	244096.66

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

Director

DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

Director

DIN:- 00137075



28. The Management is of the opinion that there is reasonable uncertainty as to the utilization of deferred tax in the near future. Hence, the Company does not intend to create any deferred tax assets as per Accounting Standard-22, as specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, for the year under review.
29. Enterprises consolidated as subsidiary and as associates in accordance with Accounting Standard 23 - Accounting for Investments in Associates in Consolidated Financial Statements, respectively:

Name of the Enterprise	Proportion of ownership interest
<u>Associate:</u>	
Reema Gases Private Limited	28.62%
C. K. Trade-Ex Private Limited	24.29%

30. The Management is of the opinion that, all assets other than Tangible Fixed Assets and Non-Current Investments have a value in realization in the ordinary course of business at least equal to the amounts at which they are stated in the Balance Sheet. Hence, none of the assets of the company has been considered as impaired during the year as per Accounting Standard (AS)-28 'Impairment of Assets' as specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
31. Additional Information, as required under Schedule III to the Companies Act, 2013, of enterprises consolidated as Subsidiary:

Name of the Enterprise	Net Assets i.e. total assets minus total liabilities		Share in profit or loss	
	As % of consolidated net assets	(₹ in Hundred)	As % of consolidated profit or loss	(₹ in Hundred)
<u>Parent:</u> Suraksha Diagnostic & Eye Centre Private Limited	59.52	1010453.55	100.11	55182.00
<u>Associates (Investments as per the equity method):</u>				
<u>Indian:</u> Reema Gases Private Limited	8.03	136272.96	(0.28)	(153.25)
C. K. Trade-Ex Private Limited	32.45	550983.06	0.17	92.04

32. Based on information available with the Company, there are no dues to "Micro and Small Enterprises" as defined under the "Micro, Small and Medium Enterprises Development Act, 2006". There is also no interest paid or payable to Micro and Small Enterprises.
33. The balances of Trade Receivables, Trade Payables, Advances, Deposits, etc. are subject to confirmation and subsequent adjustment, if any, on reconciliation.
34. Previous year's figures have been regrouped / rearranged, wherever necessary in order to make them comparable with those of the current year.

FOR K. S. BOTHRA & CO.
CHARTERED ACCOUNTANTS
FIRM REGISTRATION NO. 304084E

(A. VERMA)
PARTNER
MEMBERSHIP NO. 061326
ICAI UDIN: 23061326BGVMAB6211
KOLKATA, THE 23RD DAY OF SEPTEMBER, 2023



For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
Director
DIN:- 00137133

For Suraksha Diagnostic & Eye Centre (Pvt) Ltd.

[Signature]
Director
DIN:- 00137075